- Home
- SPHR vs APLS Comparison
SPHR vs APLS Comparison
Compare SPHR & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHR | APLS |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.2B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPHR | APLS |
|---|---|---|
| Price | $135.85 | $41.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 21 |
| Target Price | ★ $116.18 | $33.59 |
| AVG Volume (30 Days) | 652.6K | ★ 6.7M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.03 | 112.50 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $1,220,045,000.00 | $1,003,782,000.00 |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $2.04 | $18.19 |
| P/E Ratio | ★ N/A | $273.60 |
| Revenue Growth | 18.81 | ★ 28.46 |
| 52 Week Low | $35.58 | $16.61 |
| 52 Week High | $149.00 | $41.14 |
Technical Indicators
Market Signals| Indicator | SPHR | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 84.57 |
| Support Level | $125.37 | $19.29 |
| Resistance Level | $137.30 | $41.14 |
| Average True Range (ATR) | 7.49 | 0.06 |
| MACD | -1.12 | -0.65 |
| Stochastic Oscillator | 42.35 | 58.33 |
Price Performance
Historical ComparisonAbout SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments: Sphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).